Tag Archives: Dementias Platform UK (DPUK)

Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)

Posted on June 28, 2017 by Dementia and Elderly Care News

Summary The Deep and Frequent Phenotyping Study aims to discover new ways of diagnosing dementia, ideally decades before the symptoms become apparent in order to give future drug treatments the best chance of working. The Deep and Frequent Phenotyping Study … Continue reading →

Posted in Alzheimer's Society, BBC News, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, NIHR, Quick Insights, UK, Universal Interest | Tagged Ageing Population, Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Amnestic Mild Cognitive Impairment (a-MCI), Amnestic Mild Cognitive Impairment (aMCI), Applications of Big Data, BBC Radio, BBC Radio 4, BBC's World At One Programme, Big Data Analytics, Big Data Funding and Research, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Neuropsychological Test Automated Battery (CANTAB), Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Deep and Frequent Phenotyping Study (DFP), Deep and Frequent Phenotyping; Combinatorial Biomarkers of Dementia, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, DFP Study Team, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Gait and Cognition, Gait Changes, Gateway to Research (GtR), Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, Join Dementia Research, Join Dementia Research: Clinical Trials Matchmaker Service, Join Dementia Research: Recruitment Onto Dementia Studies, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurobiology of Aging (Journal), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Open Data and Big Data, Ophthalmological Assessments, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, PharmaCog Consortium, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Clare Mackay: Imaging Neuroscience at the University of Oxford, Professor Lynn Rochester: Clinical Ageing Research Unit at Newcastle University, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Publicly-Funded UK Big Data Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Screening Tools for Amnestic Mild Cognitive Impairment (a-MCI), Surrogate Biomarkers of Neurodegeneration, Translational Research, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology) | Leave a comment

New Drugs for Dementia (POST Note PN 535)

Posted on August 29, 2016 by Dementia and Elderly Care News

Summary The Parliamentary Office of Science and Technology (POST) has produced a briefing outlining some of the challenges in developing new drugs for dementia, explained in the context of ongoing UK and international research programmes. There is an extensive bibliography, … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Academic Institutes in the UK, Academy of Social Sciences, Aducanumab (Biogen), Alzheimer’s Association, Alzheimer’s Research UK’s Drug Discovery Alliance, Behavioural and Psychological Symptoms of Dementia (BPSD), Big Data, Big Data Funding and Research, Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, British Psychological Society (BPS), Co-ordination and Data Analytics, Cognitive Health in Ageing Register for Investigations, Collaborative Projects, Collaborative Research, Dementia Consortium, Dementia Risk Prevention, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), DPUK: Dementias Platform UK, Drug Discovery Alliance, Drug Licensing Approval, Drugs for BPSD, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, EAMS: Early Access to Medicines Scheme, Early Access to Medicines Scheme, Effective Non-Drug Interventions, Etanercept, European Prevention of Alzheimer's Dementia Consortium (EPAD), European Prevention of Alzheimer’s Dementia Consortium, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Join Dementia Research, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, New Drugs for Dementia (POST Note PN 535), NIHR Clinical Research Network, Observations & Trials in Dementia Research, Parliament, Parliamentary Office of Science & Technology, Parliamentary Office of Science & Technology (POST), Participation in Research, Patient Access to New Drugs, Pharmaceutical Industry, Pioglitazone, POST: Parliamentary Office of Science & Technology, Pre-Symptomatic Diagnosis of Dementia, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Prevention, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Solanezumab (Eli Lilly), Symptom-Modifying Drugs for Dementia, UK Dementia Research Institute, UK Parliament, UK Patient Recruitment Initiatives, Verubecestat (Merck), Well-Being and Health for People With Dementia (WHELD) Program | Leave a comment

Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)

Posted on August 22, 2016 by Dementia and Elderly Care News

Summary The Deep and Frequent Phenotyping Study will explore improvements in biomarker research and the development of tests to detect Alzheimer’s Disease early on. This research programme will be funded by the National Institute of Health Research (NIHR) and the … Continue reading →

Posted in Alzheimer's Society, Charitable Bodies, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, National, NIHR, Quick Insights, UK, Universal Interest | Tagged Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Aridhia, AstraZeneca / MedImmune, Berry Consultants, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Cognition, Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Dr Rob Buckle: Director of Science Programmes at MRC, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Exprodo, Gait and Cognition, Gait Changes, Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, IXICO, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Ophthalmological Assessments, Optos, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Chris Whitty: Chief Scientific Adviser at Department of Health, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Sage Bionetworks, Surrogate Biomarkers of Neurodegeneration, Translational Research, TrialSpark, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology), West London Mental Health Trust / Imperial College London | 1 Comment

Two Further Improvements: Dementia Services Seven Days a Week / Dementia Awareness for People Aged Over Forty (BBC News / Department of Health)

Posted on March 14, 2016 by Dementia and Elderly Care News

Summary Two further aspects of the latest implementation plans for the Prime Minister’s Challenge on Dementia 2020 were emphasised a week ago. Seven day NHS services are planned to benefit dementia patients, with more frequent patient assessments and better care … Continue reading →

Latest Challenge on Dementia 2020 Implementation Plan (BBC News / Department of Health)

Posted on March 7, 2016 by Dementia and Elderly Care News

Summary The Prime Minister’s Challenge on Dementia 2020 contained over 50 commitments towards making England the best place in the world for dementia care, research and societal dementia awareness by 2020. The Department of Health’s updated implementation plan specifies how … Continue reading →

Posted in Acute Hospitals, Alzheimer's Society, Alzheimer’s Research UK, BBC News, Charitable Bodies, Commissioning, Community Care, Department of Health, Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, NHS England, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Personalisation, Quick Insights, Standards, UK, Universal Interest | Tagged Achieving Dementia Friendly Acute care, Ageing and Dementia, Ageing and Society, Ageing Policy in the UK, Ageing Population, Alistair Burns: NHS England’s National Clinical Director for Dementia, Alzheimer's Association, Alzheimer’s Research UK (ARUK), Alzheimer’s Society Connecting Communities Project, Awareness and Understanding, Awareness Campaigns, BBC Health News, Behavioural Risk Factors, Behavioural Risk Factors and Dementia, Better Care Fund, Black Asian and Minority Ethnic (BAME), Black Asian and Minority Ethnic Communities (UK), British Prime Minister's Office, Building Dementia Friendly Communities, Burden of Dementia, Care and Compassion, Care at Home, Carer Support, Carer Support Services, CCG Improvement and Assessment Framework (CCGIAF), Challenge on Dementia (David Cameron), Challenge on Dementia 2020, Challenge on Dementia 2020 Implementation Plan, Citizen Participation, Collaboration, Collaborative Projects, Collaborative Research, Collaborative Working, Commitment to Carers (NHS England), Community Participation, Compassionate Care, Connecting Communities, Connecting Communities Initiative, Creating Dementia Friendly Environments, Creating Dementia Friendly Hospitals, Cross-Sector Partnerships, David Cameron, DEEP2: Dementia Engagement and Empowerment Project, Dementia 2020 Citizens’ Panel, Dementia Action Alliance (DAA), Dementia Advisers, Dementia Advisor, Dementia Advisor Service, Dementia Awareness, Dementia Awareness Training, Dementia Challenge, Dementia Consortium, Dementia Friendly Charters, Dementia Friends, Dementia Friends Campaign, Dementia Friends Champions, Dementia Friends Programme, Dementia Health and Care Champion Group, Dementia Intelligence Network (DIN), Dementia Profile Tool, Dementia Programme Board, Dementia Research, Dementia Research Institute, Dementia Risk Factors, Dementia State of the Nation, Dementia UK, Dementia Voice, Dementia-Friendly Businesses, Dementia-Friendly Care Homes, Dementia-Friendly Cities, Dementia-Friendly Communities, Dementia-Friendly Employers, Dementia-Friendly Hospitals, Dementia-Friendly Housing, Dementia-Friendly Neighbourhoods, Dementia-Friendly Sectors, Dementia-Friendly Towns, Dementias Platform UK, Dementias Platform UK (DPUK), Department of Health Dementia Challenge, Department of Health Dementia Challenge (2020), Dignity in Care, Dignity in Dementia, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Elderly Human Rights, Global Action Against Dementia, Global Burden of Dementia, Global Clinical Trials Fund (GCTF), Global Fund on Dementia, Global Leadership, Global Outlook, Healthy Behaviours, Healthy Communities, Healthy Lifestyles, Improving Care for People with Dementia, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, Integration of Health and Care, International Collaborations, International Dementia Research Inventories, International Programmes, Involvement and Participation, Jane Ellison, Join Dementia Research, Join Dementia Research: Recruitment Onto Dementia Studies, Joint Action on Dementia, Lifestyle Risk Factors, Local Dementia Action Alliances, Local Dementia Action Alliances in England, Local Government, Local Health and Care Economies, Local Health and Care Services, Local Health and Wellbeing Boards, Loneliness and Dementia, Loneliness and Social Isolation, Maintaining Independence, NHS England CCG Improvement and Assessment Framework, NHS England's Five Year Forward View (2014), NHS England’s Commitment to Carers, NHS Five Year Forward View (5YFV), NHS Health Check, NHS Health Check Programme, Organisation for Economic Co-operation and Development (OECD), Participation in Research, Participation in Research Studies, Partnership and Collaboration, Partnership Working, Patient and Public Participation, Prime Minister's Challenge on Dementia, Prime Minister's Office, Prime Minister’s Challenge On Dementia 2020, Prime Minister’s Dementia Challenge, Professor Alistair Burns, Public Health England (PHE), Public Health England Dementia Intelligence Network, Public Participation in Research, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Stigma, Referrals, Research and Innovation, Risk Factors, Risk Factors for Alzheimer's Diseease, Risk Management, Shared Delivery Plan for Health and Social Care, Support for Carers, Sustainable Care, Sustainable Health and Care Services, Tackling Barriers to Innovation, Tide Network, Unhealthy Behaviours, Unhealthy Lifestyles, Unhealthy Living, World Dementia Council, World Dementia Envoy, World Health Organization (WHO) | Leave a comment

National Dementia Research Institute (DRI) Announced (MRC)

Posted on November 24, 2015 by Dementia and Elderly Care News

Summary The national Dementia Research Institute (DRI) will be led by the Medical Research Council (MRC). The DRI is expected to receive up to £150 million in funding and be operational by 2020. It aims to link research across leading … Continue reading →

Posted in Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, NIHR, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK | Tagged Challenge on Dementia (David Cameron), David Cameron, Dementia Research, Dementia Research Funding, Dementia Research Institute (DRI), Dementias Platform UK (DPUK), Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Global Action Against Dementia, Global Context, Global Leadership, International Dementia Research, Medical Research Council (MRC), Medical Research Council (UK), MRC: Medical Research Council, National Institute for Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Research and Development, Research and Innovation, Research Commitment, Research Funding | Leave a comment

Dementia: the R&D Landscape: Mapping UK Dementia Research and Workforce Capacity (RAND Europe / WDC / OHE)

Posted on October 27, 2015 by Dementia and Elderly Care News

Summary The Alzheimer’s Society commissioned RAND Europe to analyse the UK’s dementia research “landscape” and workforce capacity. The following report relates to the state of funding and capacity in dementia research. It covers: An audit of the types of research … Continue reading →

Tag Archives: Dementias Platform UK (DPUK)

Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)

Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)

National Dementia Research Institute (DRI) Announced (MRC)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites